AGC Biologics secures multiyear Yokohama manufacturing deal valued at hundreds of millions of dollars

• AGC Biologics secured a multi-year commercial manufacturing deal for its new Yokohama site, expected to total hundreds of millions of dollars.
• An undisclosed global drugmaker committed about half the facility’s mammalian capacity for five biologics programs, targeting at least 35 batches per year.
• Yokohama is scheduled to start operations in 2027, adding 18,000 liters of single-use bioreactor capacity to the network.
• The contract covers process transfer, scale-up, validation, regulatory work, then commercial supply for major markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AGC Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607280859PRIMZONEFULLFEED9799022) on July 28, 2026, and is solely responsible for the information contained therein.